The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)
Open accessAbstract
Cancer stem cells (CSCs), which have the potential for self-renewal, differentiation and de-differentiation, undergo epigenetic, epithelial-mesenchymal, immunological and metabolic reprogramming to adapt to the tumor microenvironment and survive host defense or therapeutic insults. Intra-tumor heterogeneity and cancer-cell plasticity give rise to therapeutic resistance and recurrence through clonal replacement and reactivation of dormant CSCs, respectively. WNT signaling cascades cross-talk with the FGF, Notch, Hedgehog and TGFβ/BMP signaling cascades and regulate expression of functional CSC markers, such as CD44, CD133 (PROM1), EPCAM and LGR5 (GPR49). Aberrant canonical and non-canonical WNT signaling in human malignancies, including breast, colorectal, gastric, lung, ovary, pancreatic, prostate and uterine cancers, leukemia and melanoma, are involved in CSC survival, bulk-tumor expansion and invasion/metastasis. WNT signaling-targeted therapeutics, such as anti-FZD1/2/5/7/8 monoclonal antibody (mAb) (vantictumab), anti-LGR5 antibody-drug conjugate (ADC) (mAb-mc-vc-PAB-MMAE), anti-PTK7 ADC (PF-06647020), anti-ROR1 mAb (cirmtuzumab), anti-RSPO3 mAb (rosmantuzumab), small-molecule porcupine inhibitors (ETC-159, WNT-C59 and WNT974), tankyrase inhibitors (AZ1366, G007-LK, NVP-TNKS656 and XAV939) and β-catenin inhibitors (BC2059, CWP232228, ICG-001 and PRI-724), are in clinical trials or preclinical studies for the treatment of patients with WNT-driven cancers. WNT signaling-targeted therapeutics are applicable for combination therapy with BCR-ABL, EGFR, FLT3, KIT or RET inhibitors to treat a subset of tyrosine kinase-driven cancers because WNT and tyrosine kinase signaling cascades converge to β-catenin for the maintenance and expansion of CSCs. WNT signaling-targeted therapeutics might also be applicable for combination therapy with immune checkpoint blockers, such as atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab and pembrolizumab, to treat cancers with immune evasion, although the context-dependent effects of WNT signaling on immunity should be carefully assessed. Omics monitoring, such as genome sequencing and transcriptome tests, immunohistochemical analyses on PD-L1 (CD274), PD-1 (PDCD1), ROR1 and nuclear β-catenin and organoid-based drug screening, is necessary to determine the appropriate WNT signaling-targeted therapeutics for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 1×
“…[epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET)] (8,9), immunological reprogramming (immuno-editing) (10,11) and metabolic reprogramming (12) to adapt to the tumor micro-environment, which is collectively defined here as ‘omics reprogrammming’ (Fig.”
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Zhan, T., Rindtorff, N., & Boutros, M. (2017) · Oncogene · doi:10.1038/onc.2016.304 · Cited by 2,626
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Hippo pathway in organ size control, tissue homeostasis, and cancer
Yu, F.-X., Zhao, B., & Guan, K.-L. (2015) · Cell · doi:10.1016/j.cell.2015.10.044 · Cited by 2,206
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Huang, S.-M. A., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009) · Nature · doi:10.1038/nature08356 · Cited by 2,037
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
Signaling mechanisms of the epithelial-mesenchymal transition
Gonzalez, D. M., & Medici, D. (2014) · Science Signaling · doi:10.1126/scisignal.2005189 · Cited by 1,721
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?
Plaks, V., Kong, N., & Werb, Z. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.02.015 · Cited by 1,557
The complex world of WNT receptor signalling
Niehrs, C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3470 · Cited by 1,492
Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer
Chen, B., Dodge, M. E., Tang, W., Lu, J., Ma, Z., Fan, C.-W., Wei, S., Hao, W., Kilgore, J., Williams, N. S., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.137 · Cited by 1,383
Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration
Barker, N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3721 · Cited by 1,357
Development and Evolution of the Human Neocortex
Lui, J. H., Hansen, D. V., & Kriegstein, A. R. (2011) · Cell · doi:10.1016/j.cell.2011.06.030 · Cited by 1,342
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Takebe, N., Miele, L., Harris, P. J., Jeong, W., Bando, H., Kahn, M., Yang, S. X., & Ivy, S. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.61 · Cited by 1,298
The epigenetics of epithelial-mesenchymal plasticity in cancer
Tam, W. L., & Weinberg, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3336 · Cited by 1,163
Yamashita, T., Ji, J., Budhu, A., Forgues, M., Yang, W., Wang, H., Jia, H., Ye, Q., Qin, L., Wauthier, E., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.12.004 · Cited by 1,149
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Recurrent R-spondin fusions in colon cancer
Seshagiri, S., Stawiski, E. W., Durinck, S., Modrusan, Z., Storm, E. E., Conboy, C. B., Chaudhuri, S., Guan, Y., Janakiraman, V., Jaiswal, B. S., et al. (2012) · Nature · doi:10.1038/nature11282 · Cited by 960
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 1×
“Immune checkpoint blockers that abrogate interactions of ligands and inhibitory receptors on CD8 + T cells are promising antitumor drugs in the clinic or clinical trials (145-151).”
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Pauli, C., Hopkins, B. D., Prandi, D., Shaw, R., Fedrizzi, T., Sboner, A., Sailer, V., Augello, M., Puca, L., Rosati, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1154 · Cited by 937
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Anagnostou, V., Smith, K. N., Forde, P. M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0828 · Cited by 896
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment
Johnson, R., & Halder, G. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4161 · Cited by 881
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms3997 · Cited by 875
Acquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862 · cited 1×
“Since resistance to tyrosine kinase inhibitors occur owing to multiple mechanisms, such as acquired drug-resistant mutations in targeted tyrosine kinases, EMT, activation of other tyrosine kinase signaling cascades to bypass targeted tyrosine kinases (4,162) and activation of WNT/β-catenin signaling cascade (Fig.”
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Notch signalling in solid tumours: a little bit of everything but not all the time
Ranganathan, P., Weaver, K. L., & Capobianco, A. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3035 · Cited by 824
WNT Signaling Pathway and Stem Cell Signaling Network
Katoh, M., & Katoh, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2316 · Cited by 796
Self-citationA distinct role for Lgr5+ stem cells in primary and metastatic colon cancer
de Sousa e Melo, F., Kurtova, A. V., Harnoss, J. M., Kljavin, N., Hoeck, J. D., Hung, J., Anderson, J. E., Storm, E. E., Modrusan, Z., Koeppen, H., et al. (2017) · Nature · doi:10.1038/nature21713 · Cited by 788
Massard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783
Cancer stem cells: The challenges ahead
Medema, J. P. (2013) · Nature Cell Biology · doi:10.1038/ncb2717 · Cited by 741
Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412070 · Cited by 717
Todaro, M., Gaggianesi, M., Catalano, V., Benfante, A., Iovino, F., Biffoni, M., Apuzzo, T., Sperduti, I., Volpe, S., Cocorullo, G., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.009 · Cited by 717
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
Miyamoto, D. T., Zheng, Y., Wittner, B. S., Lee, R. J., Zhu, H., Broderick, K. T., Desai, R., Fox, D. B., Brannigan, B. W., Trautwein, J., et al. (2015) · Science · doi:10.1126/science.aab0917 · Cited by 705
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
Stromal cells in tumor microenvironment and breast cancer
Mao, Y., Keller, E. T., Garfield, D. H., Shen, K., & Wang, J. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9415-3 · Cited by 671
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 1×
“Human/humanized monoclonal antibody (mAb) drugs, such as anti-FZD1/2/5/7/8 mAb (vantictumab/OMP-18R5) (97 I).”
FGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
Self-citationYAP and TAZ: a nexus for Hippo signaling and beyond
Hansen, C. G., Moroishi, T., & Guan, K.-L. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.05.002 · Cited by 574
Ishitani, T., Kishida, S., Hyodo-Miura, J., Ueno, N., Yasuda, J., Waterman, M., Shibuya, H., Moon, R. T., Ninomiya-Tsuji, J., & Matsumoto, K. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.131-139.2003 · Cited by 541
Roles of F-box proteins in cancer
Wang, Z., Liu, P., Inuzuka, H., & Wei, W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3700 · Cited by 523
The Intestinal Wnt/TCF Signature
Van der Flier, L. G., Sabates–Bellver, J., Oving, I., Haegebarth, A., De Palo, M., Anti, M., Van Gijn, M. E., Suijkerbuijk, S., Van de Wetering, M., Marra, G., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.08.039 · Cited by 513
Planar Cell Polarity Links Axes of Spatial Dynamics in Neural-Tube Closure
Nishimura, T., Honda, H., & Takeichi, M. (2012) · Cell · doi:10.1016/j.cell.2012.04.021 · Cited by 513
Wnt signaling in stem and cancer stem cells
Holland, J. D., Klaus, A., Garratt, A. N., & Birchmeier, W. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.01.004 · Cited by 504
McDonald, O. G., Li, X., Saunders, T., Tryggvadottir, R., Mentch, S. J., Warmoes, M. O., Word, A. E., Carrer, A., Salz, T. H., Natsume, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3753 · Cited by 494
Mammalian Ryk Is a Wnt Coreceptor Required for Stimulation of Neurite Outgrowth
Lu, W., Yamamoto, V., Ortega, B., & Baltimore, D. (2004) · Cell · doi:10.1016/j.cell.2004.09.019 · Cited by 471
Reversing T-cell Dysfunction and Exhaustion in Cancer
Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462
Non-equivalence of Wnt and R-spondin ligands during Lgr5+ intestinal stem-cell self-renewal
Yan, K. S., Janda, C. Y., Chang, J., Zheng, G. X. Y., Larkin, K. A., Luca, V. C., Chia, L. A., Mah, A. T., Han, A., Terry, J. M., et al. (2017) · Nature · doi:10.1038/nature22313 · Cited by 455
WNT/PCP signaling pathway and human cancer (Review)
Katoh, M. (2005) · Oncology Reports · doi:10.3892/or.14.6.1583 · Cited by 412
Self-citationFGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
KATOH, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 405
Self-citationAnti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., Shen, Z., Patel, N., Tai, Y.-T., Chauhan, D., et al. (2009) · Blood · doi:10.1182/blood-2008-11-191577 · Cited by 399
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
Li, S., Garrett-Bakelman, F. E., Chung, S. S., Sanders, M. A., Hricik, T., Rapaport, F., Patel, J., Dillon, R., Vijay, P., Brown, A. L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4125 · Cited by 387
Proffitt, K. D., Madan, B., Ke, Z., Pendharkar, V., Ding, L., Lee, M. A., Hannoush, R. N., & Virshup, D. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2258 · Cited by 382
Wnt-Frizzled/Planar Cell Polarity Signaling: Cellular Orientation by Facing the Wind (Wnt)
Yang, Y., & Mlodzik, M. (2015) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100814-125315 · Cited by 375
Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure
Fernández-Sánchez, M. E., Barbier, S., Whitehead, J., Béalle, G., Michel, A., Latorre-Ossa, H., Rey, C., Fouassier, L., Claperon, A., Brullé, L., et al. (2015) · Nature · doi:10.1038/nature14329 · Cited by 371
Blumenthal, A., Ehlers, S., Lauber, J., Buer, J., Lange, C., Goldmann, T., Heine, H., Brandt, E., & Reiling, N. (2006) · Blood · doi:10.1182/blood-2005-12-5046 · Cited by 371
Wnt addiction of genetically defined cancers reversed by PORCN inhibition
Madan, B., Ke, Z., Harmston, N., Ho, S. Y., Frois, A. O., Alam, J., Jeyaraj, D. A., Pendharkar, V, Ghosh, K., Virshup, I. H., et al. (2016) · Oncogene · doi:10.1038/onc.2015.280 · Cited by 341
A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma
Tammela, T., Sanchez-Rivera, F. J., Cetinbas, N. M., Wu, K., Joshi, N. S., Helenius, K., Park, Y., Azimi, R., Kerper, N. R., Wesselhoeft, R. A., et al. (2017) · Nature · doi:10.1038/nature22334 · Cited by 336
Waaler, J., Machon, O., Tumova, L., Dinh, H., Korinek, V., Wilson, S. R., Paulsen, J. E., Pedersen, N. M., Eide, T. J., Machonova, O., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3336 · Cited by 328
A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4562 · Cited by 316
A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis
Li, C., Wang, S., Xing, Z., Lin, A., Liang, K., Song, J., Hu, Q., Yao, J., Chen, Z., Park, P. K., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3464 · Cited by 316
Recurrent and functional regulatory mutations in breast cancer
Rheinbay, E., Parasuraman, P., Grimsby, J., Tiao, G., Engreitz, J. M., Kim, J., Lawrence, M. S., Taylor-Weiner, A., Rodriguez-Cuevas, S., Rosenberg, M., et al. (2017) · Nature · doi:10.1038/nature22992 · Cited by 307
The role of tumor microenvironment in therapeutic resistance
Son, B., Lee, S., Youn, H., Kim, E., Kim, W., & Youn, B. (2017) · Oncotarget · doi:10.18632/oncotarget.13907 · Cited by 300
Steinhart, Z., Pavlovic, Z., Chandrashekhar, M., Hart, T., Wang, X., Zhang, X., Robitaille, M., Brown, K. R., Jaksani, S., Overmeer, R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4219 · Cited by 297
ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth
Zhang, S., Chen, L., Cui, B., Chuang, H.-Y., Yu, J., Wang-Rodriguez, J., Tang, L., Chen, G., Basak, G. W., & Kipps, T. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031127 · Cited by 260
Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28
Le, P. N., McDermott, J. D., & Jimeno, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.005 · Cited by 253
Ror receptor tyrosine kinases: orphans no more
Green, J. L., Kuntz, S. G., & Sternberg, P. W. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.006 · Cited by 252
Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function
Storm, E. E., Durinck, S., de Sousa e Melo, F., Tremayne, J., Kljavin, N., Tan, C., Ye, X., Chiu, C., Pham, T., Hongo, J.-A., et al. (2016) · Nature · doi:10.1038/nature16466 · Cited by 249
Targeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt Signaling
Takada, K., Zhu, D., Bird, G. H., Sukhdeo, K., Zhao, J.-J., Mani, M., Lemieux, M., Carrasco, D. E., Ryan, J., Horst, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003808 · Cited by 245
Yang, K., Wang, X., Zhang, H., Wang, Z., Nan, G., Li, Y., Zhang, F., Mohammed, M. K., Haydon, R. C., Luu, H. H., et al. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2015.144 · Cited by 241
Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
Inman, B. A., Longo, T. A., Ramalingam, S., & Harrison, M. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1417 · Cited by 238
Isolation, identification, and characterization of cancer stem cells: A review
Abbaszadegan, M. R., Bagheri, V., Razavi, M. S., Momtazi, A. A., Sahebkar, A., & Gholamin, M. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25759 · Cited by 225
Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation
Coluccia, A. M. L., Vacca, A., Duñach, M., Mologni, L., Redaelli, S., Bustos, V. H., Benati, D., Pinna, L. A., & Gambacorti‐Passerini, C. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601485 · Cited by 217
Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma
Sukhdeo, K., Mani, M., Zhang, Y., Dutta, J., Yasui, H., Rooney, M. D., Carrasco, D. E., Zheng, M., He, H., Tai, Y.-T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610299104 · Cited by 216
The kinase TNIK is an essential activator of Wnt target genes
Mahmoudi, T., Li, V. S. W., Ng, S. S., Taouatas, N., Vries, R. G. J., Mohammed, S., Heck, A. J., & Clevers, H. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.285 · Cited by 209
Molecular genetics and targeted therapy of WNT-related human diseases (Review)
Katoh, M., & Katoh, M. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3071 · Cited by 207
Self-citationTankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins
Wang, W., Li, N., Li, X., Tran, M. K., Han, X., & Chen, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.014 · Cited by 206
Therapeutics Targeting FGF Signaling Network in Human Diseases
Katoh, M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.003 · Cited by 204
Self-citationK-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling
Wang, M.-T., Holderfield, M., Galeas, J., Delrosario, R., To, M. D., Balmain, A., & McCormick, F. (2015) · Cell · doi:10.1016/j.cell.2015.10.041 · Cited by 196
Wnt Signaling and the Control of Human Stem Cell Fate
Van Camp, J. K., Beckers, S., Zegers, D., & Van Hul, W. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-013-9486-8 · Cited by 196
Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance
Nagaraj, A. B., Joseph, P., Kovalenko, O., Singh, S., Armstrong, A., Redline, R., Resnick, K., Zanotti, K., Waggoner, S., & DiFeo, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4690 · Cited by 195
Fang, L., Zhu, Q., Neuenschwander, M., Specker, E., Wulf-Goldenberg, A., Weis, W. I., von Kries, J. P., & Birchmeier, W. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1519 · Cited by 190
Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation
Yu, J., Chen, L., Cui, B., Widhopf, G. F., Shen, Z., Wu, R., Zhang, L., Zhang, S., Briggs, S. P., & Kipps, T. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83535 · Cited by 188
WNT-5A: signaling and functions in health and disease
Kumawat, K., & Gosens, R. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2076-y · Cited by 186
Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy
Zhang, S., Cui, B., Lai, H., Liu, G., Ghia, E. M., Widhopf, G. F., Zhang, Z., Wu, C. C. N., Chen, L., Wu, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419599111 · Cited by 186
Dijksterhuis, J. P., Petersen, J., & Schulte, G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12364 · Cited by 182
Scholz, B., Korn, C., Wojtarowicz, J., Mogler, C., Augustin, I., Boutros, M., Niehrs, C., & Augustin, H. G. (2016) · Developmental Cell · doi:10.1016/j.devcel.2015.12.015 · Cited by 182
Holtzhausen, A., Zhao, F., Evans, K. S., Tsutsui, M., Orabona, C., Tyler, D. S., & Hanks, B. A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0167 · Cited by 180
The polycystin complex mediates Wnt/Ca2+ signalling
Kim, S., Nie, H., Nesin, V., Tran, U., Outeda, P., Bai, C.-X., Keeling, J., Maskey, D., Watnick, T., Wessely, O., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3363 · Cited by 180
Arqués, O., Chicote, I., Puig, I., Tenbaum, S. P., Argilés, G., Dienstmann, R., Fernández, N., Caratù, G., Matito, J., Silberschmidt, D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3081 · Cited by 178
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Anastas, J. N., Kulikauskas, R. M., Tamir, T., Rizos, H., Long, G. V., von Euw, E. M., Yang, P.-T., Chen, H.-W., Haydu, L., Toroni, R. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70156 · Cited by 176
β-Catenin-Independent Roles of Wnt/LRP6 Signaling
Acebron, S. P., & Niehrs, C. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.07.009 · Cited by 175
Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C., & Riddell, S. R. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0163 · Cited by 173
Synovial Sarcoma: Recent Discoveries as a Roadmap to New Avenues for Therapy
Nielsen, T. O., Poulin, N. M., & Ladanyi, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1246 · Cited by 172
Valenti, G., Quinn, H. M., Heynen, G. J. J. E., Lan, L., Holland, J. D., Vogel, R., Wulf-Goldenberg, A., & Birchmeier, W. (2017) · Cancer Research · doi:10.1158/0008-5472.can-15-3490 · Cited by 171
Bicocca, V. T., Chang, B. H., Masouleh, B. K., Muschen, M., Loriaux, M. M., Druker, B. J., & Tyner, J. W. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.027 · Cited by 170
Durvalumab: First Global Approval
Syed, Y. Y. (2017) · Drugs · doi:10.1007/s40265-017-0782-5 · Cited by 170
LGR5 positivity defines stem-like cells in colorectal cancer
Hirsch, D., Barker, N., McNeil, N., Hu, Y., Camps, J., McKinnon, K., Clevers, H., Ried, T., & Gaiser, T. (2014) · Carcinogenesis · doi:10.1093/carcin/bgt377 · Cited by 168
Hwang, S.-Y., Deng, X., Byun, S., Lee, C., Lee, S.-J., Suh, H., Zhang, J., Kang, Q., Zhang, T., Westover, K. D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.071 · Cited by 164
Damelin, M., Bankovich, A., Bernstein, J., Lucas, J., Chen, L., Williams, S., Park, A., Aguilar, J., Ernstoff, E., Charati, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2611 · Cited by 163
D’Amico, L., Mahajan, S., Capietto, A.-H., Yang, Z., Zamani, A., Ricci, B., Bumpass, D. B., Meyer, M., Su, X., Wang-Gillam, A., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20150950 · Cited by 160
Targeting the WNT Signaling Pathway in Cancer Therapeutics
Tai, D., Wells, K., Arcaroli, J., Vanderbilt, C., Aisner, D. L., Messersmith, W. A., & Lieu, C. H. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0057 · Cited by 159
AXIN1 and AXIN2 variants in gastrointestinal cancers
Mazzoni, S. M., & Fearon, E. R. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.018 · Cited by 157
Targeting Signaling Pathways in Cancer Stem Cells for Cancer Treatment
Koury, J., Zhong, L., & Hao, J. (2017) · Stem Cells International · doi:10.1155/2017/2925869 · Cited by 155
Lamb, R., Bonuccelli, G., Ózsvári, B., Peiris‐Pagès, M., Fiorillo, M., Smith, D. L., Bevilacqua, G., Mazzanti, C. M., McDonnell, L. A., Naccarato, A. G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5852 · Cited by 146
Avelumab: First Global Approval
Kim, E. (2017) · Drugs · doi:10.1007/s40265-017-0749-6 · Cited by 138
LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Gong, X., Azhdarinia, A., Ghosh, S. C., Xiong, W., An, Z., Liu, Q., & Carmon, K. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0114 · Cited by 130
Daple is a novel non-receptor GEF required for trimeric G protein activation in Wnt signaling
Aznar, N., Midde, K., Dunkel, Y., López-Sánchez, I., Pavlova, Y., Marivin, A., Barbazán, J., Murray, F., Nitsche, U., Janssen, K., et al. (2015) · eLife · doi:10.7554/elife.07091 · Cited by 122
Ror2 as a Therapeutic Target in Cancer
Debebe, Z., & Rathmell, W. K. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.010 · Cited by 113
Minegishi, K., Hashimoto, M., Ajima, R., Takaoka, K., Shinohara, K., Ikawa, Y., Nishimura, H., McMahon, A. P., Willert, K., Okada, Y., et al. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.02.010 · Cited by 107
Making, Exporting, and Modulating Wnts
Langton, P. F., Kakugawa, S., & Vincent, J. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.05.011 · Cited by 106
The receptor tyrosine kinase ROR1 – An oncofetal antigen for targeted cancer therapy
Hojjat‐Farsangi, M., Moshfegh, A., Daneshmanesh, A. H., Khan, A. S., Mikaelsson, E., Österborg, A., & Mellstedt, H. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.005 · Cited by 104
SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma
Trautmann, M., Sievers, E., Aretz, S., Kindler, D., Michels, S. Y. F., Friedrichs, N., Renner, M., Kirfel, J., Steiner, S., Huss, S., et al. (2013) · Oncogene · doi:10.1038/onc.2013.443 · Cited by 102
Fiskus, W. C., Sharma, S., Saha, S., Shah, B. N., Devaraj, S. G. T., Sun, B., Horrigan, S. K., Leveque, C. M., Zu, Y., Iyer, S. P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.340 · Cited by 102
The Wnts of change: How Wnts regulate phenotype switching in melanoma
Webster, M. R., Kugel, C. H., & Weeraratna, A. T. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.10.002 · Cited by 94
RSPO3 expands intestinal stem cell and niche compartments and drives tumorigenesis
Hilkens, J., Timmer, N. C., Boer, M., Ikink, G. J., Schewe, M., Sacchetti, A., Koppens, M. A. J., Song, J., & Bakker, E. R. M. (2016) · Gut · doi:10.1136/gutjnl-2016-311606 · Cited by 93
Zhou, H., Mak, P. Y., Mu, H., Mak, D. H. F., Zeng, Z., Cortes, J. E., Liu, Q., Andreeff, M., & Carter, B. Z. (2017) · Leukemia · doi:10.1038/leu.2017.87 · Cited by 93
ADP-Ribosyltransferases and Poly ADP-Ribosylation
Liu, C., & Yu, X. (2015) · Current Protein and Peptide Science · doi:10.2174/1389203716666150504122435 · Cited by 91
β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations
Nakayama, S., Sng, N., Carretero, J., Welner, R. S., Hayashi, Y., Yamamoto, M., Tan, A. J., Yamaguchi, N., Yasuda, H., Li, D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0184 · Cited by 91
ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1
Yamaguchi, T., Lu, C., Ida, L., Yanagisawa, K., Usukura, J., Cheng, J., Hotta, N., Shimada, Y., Isomura, H., Suzuki, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms10060 · Cited by 91
Gastrointestinal organoids: How they gut it out
Merker, S. R., Weitz, J., & Stange, D. E. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2016.08.010 · Cited by 83
Wang, H., Lu, B., Cabrera, J. C., Zhang, Y., Yang, Z., McAllister, G., Lindeman, A., Reece-Hoyes, J. S., Tallarico, J. A., Russ, C., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.722967 · Cited by 80
Katoh, M., Kirikoshi, H., Terasaki, H., & Shiokawa, K. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6076 · Cited by 78
Self-citationKim, J., Lee, H., Park, K.-K., Choi, Y., Nam, J., & Hong, I. (2016) · Oncotarget · doi:10.18632/oncotarget.7954 · Cited by 74
Cloning, expression and chromosomal localization of Wnt-13, a novel member of the Wnt gene family.
Katoh, M., Hirai, M., Sugimura, T., & Terada, M. (1996) · PubMed · Cited by 74
Self-citationKulak, O., Chen, H., Holohan, B., Wu, X., He, H., Borek, D., Otwinowski, Z., Yamaguchi, K., Garofalo, L. A., Ma, Z., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00392-15 · Cited by 71
Wnt5a promotes Frizzled-4 signalosome assembly by stabilizing cysteine-rich domain dimerizationPreprint
DeBruine, Z. J., Ke, J., Harikumar, K. G., Gu, X., Borowsky, P., Williams, B. O., Xu, W., Miller, L. J., Xu, H. E., & Melcher, K. (2017) · Genes & Development · doi:10.1101/gad.298331.117 · Cited by 71
Agarwal, P., Zhang, B., Ho, Y., Cook, A., Li, L., Mikhail, F. M., Wang, Y., McLaughlin, M. E., & Bhatia, R. (2016) · Blood · doi:10.1182/blood-2016-05-714089 · Cited by 69
Cheng, Y., Phoon, Y. P., Jin, X. A., Chong, S. Y. S., Ip, J. C. Y., Wong, B. W. Y., & Lung, M. L. (2015) · Oncotarget · doi:10.18632/oncotarget.3982 · Cited by 65
WNT-3A Regulates an Axin1/NRF2 Complex That Regulates Antioxidant Metabolism in Hepatocytes
Rada, P., Rojo, A. I., Offergeld, A., Feng, G. J., Velasco-Martin, J. P., González‐Sancho, J. M., Valverde, Á. M., Dale, T. C., Regadera, J., & Cuadrado, A. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6040 · Cited by 65
Mani, S. K. K., Zhang, H., Diab, A., Pascuzzi, P. E., Lefrançois, L., Farés, N., Bancel, B., Merle, P., & ANDRISANI, O. M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.022 · Cited by 64
Marco, P. D., Merello, E., Piatelli, G., Cama, A., Kibar, Z., & Capra, V. (2014) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.23255 · Cited by 61
Nathubhai, A., Haikarainen, T., Koivunen, J. T., Murthy, S., Koumanov, F., Lloyd, M. D., Holman, G. D., Pihlajaniemi, T. A., Tosh, D., Lehtiö, L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01574 · Cited by 58
Scarborough, H. A., Helfrich, B. A., Casás‐Selves, M., Schuller, A. G., Grosskurth, S. E., Kim, J., Tan, A. C., Chan, D. C. F., Zhang, Z., Zaberezhnyy, V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1179 · Cited by 57
CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells
Zhao, Y., Masiello, D., McMillian, M., Nguyen, C., Wu, Y., Melendez, E., Smbatyan, G., Kida, A., He, Y. J., Teo, J.-L., et al. (2015) · Oncogene · doi:10.1038/onc.2015.438 · Cited by 52
Establishing estrogen-responsive mouse mammary organoids from single Lgr5+ cells
Zhang, L., Adileh, M., Martín, M. L., Klingler, S., White, J. R., Ma, X., Howe, L. R., Brown, A. M. C., & Kolesnick, R. N. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.08.001 · Cited by 52
The ROR1 pseudokinase diversifies signaling outputs in MET‐addicted cancer cells
Gentile, A., Lazzari, L., Benvenuti, S., Trusolino, L., & Comoglio, P. M. (2014) · International Journal of Cancer · doi:10.1002/ijc.28879 · Cited by 49
Schoumacher, M., Hurov, K. E., Lehár, J., Yan‐Neale, Y., Mishina, Y. M., Sonkin, D., Korn, J. M., Flemming, D., Jones, M. D., Antonakos, B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0138-t · Cited by 47
Protein Depalmitoylation Is Induced by Wnt5a and Promotes Polarized Cell Behavior
Wang, W., Runkle, K. B., Terkowski, S. M., Ekaireb, R. I., & Witze, E. S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.639609 · Cited by 46
Zhang, M., Hagenmueller, M., Riffel, J. H., Kreußer, M. M., Bernhold, E., Fan, J., Katus, H. A., Backs, J., & Hardt, S. E. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04467 · Cited by 46
Quackenbush, K. S., Bagby, S. M., Tai, W. M. D., Messersmith, W. A., Schreiber, A., Greene, J., Kim, J., Wang, G., Purkey, A., Pitts, T. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8626 · Cited by 43
Jin, B., Ding, K., & Pan, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0397 · Cited by 41
Tan, Z., Chen, L., & Zhang, S. (2016) · Scientific Reports · doi:10.1038/srep33534 · Cited by 38
Gong, B., Shen, W., Xiao, W., Meng, Y., Meng, A., & Jia, S. (2017) · eLife · doi:10.7554/elife.26362 · Cited by 38
Wang, Q., Amato, S., Rubitski, D. M., Hayward, M. M., Kormos, B. L., Verhoest, P. R., Xu, L., Brandon, N. J., & Ehlers, M. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229880 · Cited by 35
FZD10-Gα13 signalling axis points to a role of FZD10 in CNS angiogenesis
Hot, B., Valnohová, J., Arthofer, E., Simon, K., Shin, J., Uhlén, M., Kostenis, E., Mulder, J., & Schulte, G. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.01.023 · Cited by 33
Lee, Y., Jung, J.-I., Park, K.-Y., Kim, S. A., & Kim, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17056 · Cited by 29
Wnt Signaling through the Ror Receptor in the Nervous System
Petrova, I. M., Malessy, M. J. A., Verhaagen, J., Fradkin, L. G., & Noordermeer, J. N. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8520-9 · Cited by 28
Kajiguchi, T., Katsumi, A., Tanizaki, R., Kiyoi, H., & Naoe, T. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01738.x · Cited by 26
Chiche, A., Moumen, M., Romagnoli, M., Petit, V., Lasla, H., Jézéquel, P., de la Grange, P., Jonkers, J., Deugnier, M., Glukhova, M. A., et al. (2016) · Oncogene · doi:10.1038/onc.2016.396 · Cited by 26
Dissecting the role of polarity regulators in cancer through the use of mouse models
Gödde, N., Pearson, H. B., Smith, L. K., & Humbert, P. O. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.036 · Cited by 24
Pharmacophore Model for Wnt/Porcupine Inhibitors and Its Use in Drug Design
Poulsen, A., Ho, S. Y., Wang, W., Alam, J., Jeyaraj, D. A., Ang, S. H., Tan, E. S. W., Lin, G. R., Cheong, V. W. W., Ke, Z., et al. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00159 · Cited by 20
Bendell, J. C., Murphy, J. E., Mahalingam, D., Halmos, B., Sirard, C. A., Landau, S. B., & Ryan, D. P. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.111 · Cited by 20
Wang, L., Steele, I. A., Kumar, J. D., Dimaline, R., Jithesh, P. V., Tiszlavicz, L., Reisz, Z., Dockray, G. J., & Varró, A. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00443.2015 · Cited by 18
Regulation of lipid synthesis by the RNA helicase Mov10 controls Wnt5a production
Wang, W., Snyder, N. W., Worth, A. J., Blair, I. A., & Witze, E. S. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.15 · Cited by 15
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Wnt signaling in colorectal cancer: Pathogenic role and therapeutic target
Zhao, H., Ming, T., Tang, S., Ren, S., Yang, H., Liu, M., Tao, Q., & Xu, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01616-7 · Cited by 857
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Jung, Y.-S., & Park, J.-I. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0380-6 · Cited by 419
CircRNAs: role in human diseases and potential use as biomarkers
Verduci, L., Tarcitano, E., Strano, S., Yarden, Y., & Blandino, G. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03743-3 · Cited by 374
Metadata
- Authors
- Katoh, M.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2017-09-19
- Volume
- 51
- Issue
- 5
- Pages
- 1357-1369
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W2755285110
- Cited by
- 465
- References
- 164
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.